WASHINGTON (dpa-AFX) - Zimmer Biomet Holdings Inc. (ZBH) said that its board
has approved a new stock repurchase authorization, granting the company
authority to repurchase up to $2 billion in common stock.

At 2024 Investor Day event, Zimmer Biomet provided its long-range plan for 2024
through 2027, including delivering Mid-single-digit percentage constant currency
consolidated revenue compound annual growth rate (CAGR); Adjusted earnings per
share growth at least 1.5 times revenue growth; Free Cash Flow growing at least
100 basis points faster than adjusted earnings per share.

Zimmer Biomet also announced that it has formalized a partnership with CBRE
Group Inc. (CBRE) to develop and outfit orthopedic ambulatory surgery centers in
the U.S.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX